Background: Lopinavir/ritonavir is a protease inhibitor (PI) that has shown great effectiveness as salvage therapy in PI-experienced HIV-infected children.
Introduction
Protease inhibitors (PIs) are very efficient in controlling human immunodeficiency virus (HIV)-1 viral replication, but the use of PIs as salvage therapy for heavily pre-treated patients has not fulfilled its expectations. 1 However, lopinavir/ritonavir has shown great effectiveness as salvage therapy in PI-experienced HIV-infected children. [2] [3] [4] Partial PI resistance accumulated during prior therapy can result in resistance to lopinavir. 5 The exact pattern of lopinavir resistance is not yet known and may provide a prediction of virological response to lopinavir/ritonavir. [6] [7] [8] [9] [10] Genotyping analyses have revealed that mutations in 16 amino acids of the HIV-1 protease gene (L10F/I/R/V, K20M/R, L24I, V32I, L33F, M46I/L, I47V/A, I50V, F53L, I54V/L/A/M/T/S/I, L63P, A71V/T, G73S, V82A/F/T/S, I84V and L90M), called 'lopinavir mutation score' (LMS) are likely to contribute to the reduced susceptibility to lopinavir, 11 and provide a potential method as a baseline genotype to evaluate the hypothetical virological response to lopinavir/ ritonavir. Other potential predictors include the protease-associated mutations (PRAMs) that evaluate mutations at codons L33 I/V or F, 82L/T, 84V or 90M which are associated with a high level of cross-resistance. 12 To address the predictive value of PI mutations on viral load (VL) response to salvage therapy, we have carried out a study with PI-experienced HIV-infected children treated with lopinavir/ ritonavir and followed up for a long period of time (24 months).
Patients and methods

Patients and study design
The study involved a multicentre prospective cohort of 56 PIexperienced HIV-infected children on salvage therapy with lopinavir/ritonavir followed at 12 Spanish hospitals. The inclusion criteria were: (i) VL > 5000 copies/mL at baseline; (ii) at least 6 months of follow-up; (iii) older than 1 year of age; (iv) being previously treated with antiretroviral therapies (ART) and having records of virological failure with PI and/or non-nucleoside analogue (NNRTI); (v) starting salvage HAART (highly active antiretroviral therapy) with lopinavir/ ritonavir; (vi) no CD4+ cell count restrictions. This study was conducted according to the declaration of Helsinki and was approved by the Ethics Committees of all hospitals involved.
The children were monitored at least every 3 months with physical examinations and blood sample collection for serial measurements as previously described. 13 Laboratory markers of HIV-1 infection (T cells subsets, VL and genotypic HIV-1 drug resistance) were measured as previously described. 13 There was not a uniform approach regarding antiretroviral treatment in the background regimen given together with lopinavir/ritonavir. Instead, each paediatrician administered the appropriate antiretroviral therapy (ART) regimen and changed the drugs according to his/her interpretation of the data and international guidelines. 13 
HIV-1 VL
VL was measured in plasma using the Amplicon Monitor assay (Amplicon Monitor; Roche Diagnostic Systems, Brandenburg, NJ, USA). The limit of quantification was 400 copies/mL.
Genotypic analysis of HIV-1 isolates
Baseline plasma samples for viral genotype were collected between day -60 (60 days prior to initiation of lopinavir/ritonavir treatment) and day 1. Genotypic HIV-1 drug resistance was determined from plasmaassociated HIV-1 RNA using the TruGene HIV-1 Resistance Kit (Visible Genetics, Toronto, Canada). The complete HIV-1 protease gene was analysed using Gene Objects software (Visible Genetics). Drug resistances were defined according to the IAS-USA consensus statement. 14 
Statistical analysis
The ANOVA test was used to compare between the means of two groups. The Fisher exact test was used for all other comparisons between groups. Differences in the characteristics among number of mutations in children were analysed using a non-parametric test (Mann-Whitney). All P values were two-tailed, and the threshold of significance was set at 0.05. The outcome variables examined were the time necessary for achieving VL £ 400 copies/mL and for maintaining VL £ 400 copies/mL for at least 6 months. These variables were analysed by the Kaplan-Meier method. Cox regression analyses were performed to assess the relative proportion (RP) achieving VL £ 400 copies/mL according to the presence of the PI mutation, and adjusted by baseline characteristics (%CD4+, VL and age at baseline, and additional new drugs in the salvage regimen at baseline). Also, we performed a logistic regression analysis to determine the odds ratio (OR) of VL control (to maintain VL £ 400 copies/mL for at least 6 months).
Results
Characteristics of HIV-1-infected children at baseline Table 1 shows the baseline characteristics of HIV-infected children enrolled in this study. Approximately 50% of children had an AIDS diagnosis. Also, 42/56 of children had CD4+ T cells ‡ 15% whereas 25/56 had VL £ 50 000 copies/mL. Throughout the follow-up period, no child progressed to a new AIDSdefining condition or death. Twenty-nine percent of HIV-infected children did not show any PRAMs whereas 59% had <6 LMS. Table 2 shows the ART regimens and drugs used with lopinavir/ ritonavir in the salvage regimen. Sixty-six percent of children had >3 ART switches prior to baseline. Stavudine (NRTI) and efavirenz (NNRTI) were the drugs most frequently used. In addition, about 50% of children took 2 NRTI + 1 PI. One year after salvage therapy with lopinavir/ritonavir, 47/56 of children continued with the same regimen they had after initiation of HAART.
Prevalence of genotypic resistances at baseline and its impact on virological response At baseline, children had a median of 5 lopinavir mutations (range: 0; 10). The most frequent PI mutations were L63A/P, A71T/V, L10I and L90M. In addition, all children had a median of 4.5 (range: 0; 8) NRTI mutations and 0 (range: 0; 3) NNRTI mutations. The most frequent reverse transcriptase (RT) mutations were M41L, D67N, Q151M, G190A and T215F.
Children with LMS ‡ 6 presented a negative association with achieving VL £ 400 copies/mL and with maintaining virological suppression (VL ‡ 400 copies/mL) for at least 6 months (Table 3) . Moreover, children with PRAMs ‡ 2 had a negative association with achieving VL £ 400 copies/mL but not with maintaining virological suppression (VL £ 400 copies/mL) for at least 6 months (Table 3) .
On the other hand, I54V (24/56 of children) and V82A/F (23/56 of children) were individually associated with virological failure. HIV-infected children with PI mutations at positions 82 and 54 had the lowest probability for achieving VL £ 400 copies/mL (Table 3 ). There was a significant negative association between the presence of I54V and V82A/F at baseline and the probability of achieving a VL < 400 copies/mL. Also, we have shown that PI mutations at positions 82 and 54 were inversely associated with maintaining virological suppression (VL £ 400 copies/mL) for at least 6 months (Table 3) . 
Virological failure with lopinavir/ritonavir
Association of I54V and V82A/F mutations and its impact on virological response
Twenty-four children showed I54V and 20 of these showed V82A/F. When we analysed the virological impact of the I54V and V82A/F mutations combined, we have shown that children with I54V and V82A/F had a high prevalence of other lopinavir mutations (L10I, K20R, L24I, V32I, L33F, M46L, L63P, A71V/T, G73S, V82A/F, I84V and L90M) (Figure 1a ). Children with both mutations had a median of 7 lopinavir mutations (range: 4; 10) in contrast to a median of 4 (range: 0; 8) in children without the two mutations (P < 0.001). Moreover, children with I54V and V82A/F mutations also showed a high prevalence of RT mutations (Figure 1b and c) . Thus, they had a median of 5 NRTI mutations (range: 2; 8) in contrast to a median of 4 (range: 0; 9) in children without I54V and V82A/F (P = 0.532). Also, HIV-infected children with I54V and V82A/F showed a median of 2 (range: 0; 2) in contrast to a median of 0 (range: 0; 3) NNRTI mutations in children without the two mutations (P = 0.018). I54V and V82A/F were associated with virological failure; so, the median time to achieve VL £ 400 copies/mL was higher with I54V and V82A/F (P = 0.005) (Figure 1c ). In addition, children with I54V and V82A/F had VL higher than children without the two mutations (P < 0.05) for the first 12 months of follow-up (Figure 1d ).
Children with I54V and V82A/F had the lowest probability of achieving VL £ 400 copies/mL (Table 3 ). I54V and V82A/F PI had a negative association with achieving undetectable VL and with having virological suppression (VL £ 400 copies/mL) for at least 6 months.
Discussion
Lopinavir/ritonavir is relatively well-tolerated, provides potent antiviral activity 3 and may be used as an effective option for the treatment of children in combination with another antiretroviral as part of salvage therapy regimens. 15 Kempf et al. 9 found that lopinavir showed a low cross-resistance pattern to other PIs in HIV-infected patients. However, we have demonstrated that a quite significant resistance can be observed in PI-experienced patients. In addition, patients who fail lopinavir may develop mutations associated with significant resistance to other PIs. Predictive factors of virological response to lopinavir/ritonavir in children are unknown, especially in children who have been pre-treated with PIs. In this study, we have shown that some PI mutations present at baseline have a predictive value for virological response.
Previous studies have shown that the 16-mutation LMS was inversely associated with virological suppression. 2, 7, 9, 13, 16, 17 Algorithms for interpreting viral genotypes have suggested that the efficacy of lopinavir/ritonavir treatment is significantly reduced by the presence of six or more mutations (www.hivdb.stanford. edu). However, one other study found that this scoring system may lead to under-appreciation of lopinavir-associated resistance. 18 Mutations at positions 46, 54 and 82 showed a great resistance to lopinavir. The threshold number of lopinavir mutations found by Delaugerre et al. 16 was 4, but we found a threshold of 6 as determinant of the virological outcome in agreement with other studies in children 13 and adults. 6, 7, 9, 19 The differences could be because the children in the Delaugerre et al. report were less heavily treated than the children in our study. 40%   60%   80%   100%   L10F  L10I  K20M  K20R  L24I  D30N  V32I  L33F  M36I/V  M46I  M46L  L63A/P  A71T/V  G73S  V77I  I84V  N88D  L90M   HIV-protease mutations   %HIV-children   0%   20%   40%   60%   80%   100%   M41L  K65R  D67N  T69N  T69D  K70R  L74V  V75I  F116Y  V118I  Q151M  M184V  L210W  T215F  T215Y  K219E/Q  L100I  K103N  Y181C  G190A HIV The number of PRAMs necessary to confer resistance to lopinavir seems to be quite low (2 or more). 20 We have found that only PRAMs ‡ 2 in plasma of children had a negative association with virological response to salvage therapy with lopinavir/ ritonavir. However, this association was not found for maintaining virological suppression for at least 6 months.
Our data clearly indicate that I54V and V82A/F mutations were associated with virological failure. These data differ from another study in children that found an association of the PI mutations L10I/F, M46I, I54V/L, A71V/I, V82A/F/T/S and L90M with virological failure. 16 Thus, in our study undetectable VL was observed more commonly in children without I54V and V82A/F PI mutations; and VL values were stable between 3 and 15 months in most of these children. In contrast, viral replication was not well controlled in children with I54V and V82A/F as indicated by the low OR for achieving undetectable VL for at least 6 months of follow-up. Children with I54V and V82A/F had been heavily pre-treated and had a high overall number of mutations against lopinavir, NRTIs and NNRTIs. We also found that HIV-infected children with I54V and V82A/F also had a high prevalence of other lopinavir mutations. 11 Moreover, we did not find any influence of previous ART at baseline and additional new drugs in the salvage regimen at baseline on the virological response because we did not find statistical significance in Cox regression analysis for achieving undetectable VL and for maintaining undetectable VL for at least 6 months (data not shown). Besides, with regard to the mutations in the HIV-1 protease gene, only VL at baseline showed statistical significance in Cox regression analysis.
In conclusion, our study indicates that both LMS and PRAMs in plasma of children were associated with virological failure to salvage therapy with lopinavir/ritonavir. Despite there being several studies, the exact pattern of lopinavir/ritonavir resistance is not yet known and the beneficial role for lopinavir/ritonavir in salvage antiretroviral therapy remains under debate. However, we have shown that I54V and V82A/F led to the worst virological response. Further studies are necessary on specific mutation patterns associated with a low response to lopinavir/ritonavir in HIV-infected children.
